作者
Fadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra, Costantine Albany, Ryan Ashkar, Heather H Cheng, Alexandra O Sokolova, Neeraj Agarwal, Adam Kessel, Alan Bryce, Nellie Nafissi, Pedro Barata, A Oliver Sartor, Diogo Bastos, Oren Smaletz, Jacob E Berchuck, Mary-Ellen Taplin, Rahul Aggarwal, Cora N Sternberg, Panagiotis J Vlachostergios, Ajjai S Alva, Christopher Su, Catherine H Marshall, Emmanuel S Antonarakis
发表日期
2021/7
期刊
JCO Precision Oncology
卷号
5
页码范围
1200-1220
出版商
Wolters Kluwer Health
简介
PURPOSE
Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied.
METHODS
We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC.
RESULTS
A total of 123 …
学术搜索中的文章
F Taza, AE Holler, W Fu, H Wang, N Adra, C Albany… - JCO Precision Oncology, 2021